Inmune Bio (INMB) Cash & Current Investments (2017 - 2026)

Inmune Bio has reported Cash & Current Investments for 10 years, with the latest figure at $21.4 million in Q1 2026.

• Quarterly Cash & Current Investments rose 10.45% year-over-year to $21.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.4 million (up 10.45% YoY) and the FY2025 annual result came in at $24.8 million, up 18.3% from the prior year.
• Cash & Current Investments eased to $21.4 million in Q1 2026 per INMB's latest filing, from $24.8 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $66.7 million in Q1 2022 and troughed at $19.3 million in Q1 2025.
• A 5-year average of $38.3 million and a median of $33.6 million in 2024 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2022 and 2024: Cash & Current Investments soared 51.1% in 2022, then tumbled 49.02% in 2024.
• Over 5 years, Cash & Current Investments stood at $52.2 million in 2022, then plunged by 31.26% to $35.8 million in 2023, then tumbled by 41.64% to $20.9 million in 2024, then climbed by 18.3% to $24.8 million in 2025, then fell by 13.71% to $21.4 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $21.4 million, $24.8 million, and $27.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.